Hidroxicarbamida Generis

Hidroxicarbamida Generis is a prescription medication whose active ingredient is hydroxycarbamide, an antimetabolite used in oral tablet form. Marketed in the European Union, this generic product contains hydroxycarbamide at the standard therapeutic strength for hematologic disorders. It belongs to the ATC class L01XX02 and is classified as a prescription‑only drug. The formulation is intended for systemic administration to manage specific blood‑cell conditions and improve patient outcomes.

Hydroxycarbamide is indicated for several hematologic disorders where reduction of abnormal blood cell production is required.

- Sickle cell disease: reduces frequency of painful vaso‑occlusive crises. - Chronic myelogenous leukemia (CML): used as part of disease‑modifying therapy. - Polycythemia vera: helps control elevated red blood cell mass. - Essential thrombocythemia: lowers platelet counts to target levels. - Occasionally prescribed for other myeloproliferative neoplasms under specialist supervision.

Adverse reactions to hydroxycarbamide vary in frequency and severity.

Common: - Nausea or vomiting - Mild gastrointestinal upset - Temporary hair thinning

Serious: - Severe bone marrow suppression (neutropenia, thrombocytopenia) - Acute renal failure - Life‑threatening infections due to immunosuppression

Hydroxycarbamide requires careful monitoring and specific precautions to minimize risks.

- Baseline and periodic complete blood counts to detect marrow suppression. - Renal and hepatic function tests before initiation and during therapy. - Avoid use in pregnancy; it is classified as Category D and may cause fetal harm. - Counsel women of childbearing potential about effective contraception. - Monitor for signs of infection or bleeding, especially in immunocompromised patients. - Adjust dose in patients with impaired kidney function. - Discontinue promptly if severe toxicity develops.

Hydroxycarbamide can interact with several medicines, affecting its efficacy or safety.

Avoid: - Concurrent use with strong CYP2C9 inhibitors (e.g., fluconazole) that may increase hydroxycarbamide levels. - Co‑administration with other myelosuppressive agents (e.g., azathioprine) that can exacerbate bone‑marrow toxicity. - Combining with nephrotoxic drugs (e.g., aminoglycosides) that raise risk of renal impairment.

Use with caution: - Anticoagulants (e.g., warfarin) – monitor coagulation parameters. - Allopurinol – may increase risk of hypersensitivity reactions. - Live vaccines – reduced immune response may occur. - NSAIDs – may increase risk of gastrointestinal irritation.